HOME >> MEDICINE >> NEWS
Molecular mechanism underlaying anthrax infection described by UCSD School Of Medicine researchers

The mechanism by which inhaled anthrax disarms and evades the immune system, enabling the potentially lethal bacteria to rapidly spread throughout the body, has been described by researchers at the University of California, San Diego (UCSD) School of Medicine.

Published online Aug. 29 in Science Express, the website of the journal Science, the lab-culture research with mouse cells describe how a complex of Bacillus anthracis (anthrax) proteins called lethal toxin (LT) inhibits and destroys macrophages, the large white blood cells that act as the body's first defense against pathogens, and also disables the signaling mechanism triggering immune activation. This allows the bacteria to spread through the body unchecked by the immune system, resulting in rapid and potentially lethal anthrax infection.

When the bacterium (b. anthracis) is inhaled, its spores are surrounded by alveolar macrophages in the lung, the beginning stage of normal immune response. But instead of succumbing to the defensive assault, they survive and germinate within the cells, traveling with the macrophages in their normal sentinel duty throughout the body to the lymph nodes, and eventually into the bloodstream, ultimately leading to fatal systemic shock if treatment fails.

In order to understand how anthrax was evading the immune system, the research team led by Michael Karin, Ph.D., UCSD professor of pharmacology and American Cancer Society Research Professor, used a variety of lab tests to determine how LT caused cell death in mouse macrophage cells. They pinpointed a series of steps, and specifically inhibition of an enzyme (a protein kinase) called p38, that lead to macrophage death and prevent secretion of chemokines and cytokines, the signaling agents that alert the immune system to the presence of an invading pathogen.

According to Karin, these findings open the door for development of an antidote that could block the action of a specific toxin called leth
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
29-Aug-2002


Page: 1 2

Related medicine news :

1. Molecular test predicts risk of breast cancer recurrence and who will benefit from chemotherapy
2. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
3. Molecular tailoring of chemotherapy with novel imaging techniques
4. Molecular clock genes influence metabolism of sugar and dietary fats
5. Data announced at ISHLT: Molecular testing proves effective in monitoring heart transplant rejection
6. Molecular analyses of leukemia patients suggest strategies for better treatments
7. Molecular test proves to be effective in measuring remission and relapse after cancer treatment
8. Molecular tag pinpoints which breast cancer tumors are most likely to spread
9. Molecularly targeted drug slows tumor growth in patients
10. Molecular self-assembly techniques used to coat biomedical substrates
11. Molecular nanogenerator developed that can target cancer cells and destroy them

Post Your Comments:
(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: